Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Rondaptivon Pegol (BT200) to Correct Thrombocytopenia in a Peri-Interventional Setting in Type 2B Von Willebrand Disease (VWD)

Miriam Moser, Cihan Ay, Christian Schoergenhofer, James C Gilbert, Shuhao Zhu, Bernd Jilma

Blood (2024) 144 (Supplement 1): 3984.

https://doi.org/10.1182/blood-2024-202611

Published: 2024

Journal Articles

The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1

Alain Chion, Ciara Byrne, Ferdows Atiq, Dearbhla Doherty, Sonia Aguila, Judicael Fazavana, Patricia Lopes, Ellie Karampini, Aamir Amin, Roger J. S. Preston, Ross I. Baker, Thomas A. J. McKinnon, Shuhao Zhu, James C. Gilbert, Jonas Emsley, Bernd Jilma, James S. O’Donnell

Blood (2024) 144 (13): 1445–1456.

https://doi.org/10.1182/blood.2024024055

Published: 2024

Includes: Supplemental data

Journal Articles

Recombinant Human Diamine Oxidase Against Histamine Induced Shock - Implications for Mast Cell Activation Syndrome

Matthias Weiss-Tessbach, Birgit Reiter, Felix Kosta, Martin Murauer, Elisabeth Gludovacz, Thomas Böhm, Bernd Jilma, Marlene Rager-Resch

Blood (2023) 142 (Supplement 1): 3914.

https://doi.org/10.1182/blood-2023-185090

Published: 2023

Journal Articles

Using a Quality Improvement Activity to Enhance the Knowledge, Competence and Confidence of Clinicians Managing Patients with Cold Agglutinin Disease

Alison Scott, Bernd Jilma, Morie A Gertz, Shirley D'Sa, Luke Boothman, Alex Noble, Kathy Day, Sadaf Kazi

Blood (2023) 142 (Supplement 1): 5066.

https://doi.org/10.1182/blood-2023-172507

Published: 2023

Journal Articles

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Cihan Ay, Katarina D. Kovacevic, Daniel Kraemmer, Christian Schoergenhofer, Georg Gelbenegger, Christa Firbas, Peter Quehenberger, Petra Jilma-Stohlawetz, James C. Gilbert, Shuhao Zhu, Martin Beliveau, Franz Koenig, Alfonso Iorio, Bernd Jilma, Ulla Derhaschnig, Ingrid Pabinger

Blood (2023) 141 (10): 1147–1158.

https://doi.org/10.1182/blood.2022016571

Published: 2023

Includes: Supplemental data

Journal Articles

Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CASCADE)

Bernd Jilma, Eloy Roman, Yasutaka Ueda, Silvia Mappa, Johan Szamosi, Jessica Savage, Alexander Roeth

Blood (2022) 140 (Supplement 1): 5326–5327.

https://doi.org/10.1182/blood-2022-155989

Published: 2022

Journal Articles

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Blood (2022) 140 (Supplement 1): 2825–2827.

https://doi.org/10.1182/blood-2022-159562

Published: 2022

Journal Articles

Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study

Alexander Roeth, Catherine M. Broome, Wilma Barcellini, Bernd Jilma, Quentin A. Hill, David Cella, Tor Henrik Anderson Tvedt, Masaki Yamaguchi, Irina Murakhovskaya, Michelle Lee, Frank Shafer, Marek Wardecki, Jennifer Wang, Ronnie Yoo, Jerome Mshijid, Ilene C. Weitz

Blood (2022) 140 (Supplement 1): 70–72.

https://doi.org/10.1182/blood-2022-159966

Published: 2022

Journal Articles

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun-ichi Nishimura, Josephine M. I. Vos, Michael Storek, Nancy Wong, Parija Patel, Xiaoyu Jiang, Deepthi S. Vagge, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome

Blood (2022) 140 (9): 980–991.

https://doi.org/10.1182/blood.2021014955

Published: 2022

Includes: Supplemental data

Journal Articles

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Blood (2021) 138 (Supplement 1): 349.

https://doi.org/10.1182/blood-2021-148066

Published: 2021

Journal Articles

Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis

Georg Obermayer, Taras Afonyushkin, Laura Göderle, Florian Puhm, Waltraud Schrottmaier, Soreen Taqi, Michael Schwameis, Cihan Ay, Ingrid Pabinger, Bernd Jilma, Alice Assinger, Nigel Mackman, Christoph J. Binder

Blood (2021) 137 (10): 1406–1415.

https://doi.org/10.1182/blood.2020007155

Published: 2021

Includes: Supplemental data

Journal Articles

Association of ABO Blood Group with Bleeding Severity in Patients with Bleeding of Unknown Cause

Dino Mehic, MD, Stefanie Hofer, PhD, Christof Jungbauer, MD, Alexandra Kaider, Helmuth Haslacher, MD, Ernst Eigenbauer, Judit Rejtoe, MD, Dieter Schwartz, MD, Bernd Jilma, Cihan Ay, MD, Ingrid Pabinger, MD, Johanna Gebhart, MD PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-137378

Published: 2020

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up

Alexander Röth, MD, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, MD, Bernd Jilma, Tor Henrik Anderson Tvedt, Ilene C. Weitz, Parija Patel, Xiaoyu Jiang, Caroline Reuter, Jun Su, Frank Shafer, Michelle Lee, William Hobbs, Sigbjørn Berentsen

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-138909

Published: 2020

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen

Blood (2019) 134 (Supplement_2): LBA-2.

https://doi.org/10.1182/blood-2019-132490

Published: 2019

Journal Articles

Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia

Bruno Fattizzo, MD, Marc Michel, Laetitia Languille, Juri Giannotta, MD, Henrik Frederiksen, MD Prof, Francesca Romana Mauro, MD, Bernd Jilma, Elisa Lucchini, MD, Andrea Patriarca, MD, Francesco Zaja, MD, Anita Hill, MD PhD, Sigbjorn Berentsen, MD PhD, Wilma Barcellini

Blood (2019) 134 (Supplement_1): 3516.

https://doi.org/10.1182/blood-2019-125524

Published: 2019

Journal Articles

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Ulrich Jäger, Shirley D’Sa, Christian Schörgenhofer, Johann Bartko, Ulla Derhaschnig, Christian Sillaber, Petra Jilma-Stohlawetz, Michael Fillitz, Thomas Schenk, Gary Patou, Sandip Panicker, Graham C. Parry, James C. Gilbert, Bernd Jilma

Blood (2019) 133 (9): 893–901.

https://doi.org/10.1182/blood-2018-06-856930

Published: 2019

Includes: Supplemental data

Journal Articles

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Ulrich Jaeger, MD, Shirley D'Sa, MD FRCP, FRCPath, Christian Schoergenhofer, MD, Johann Bartko, MD, Christian Sillaber, MD, Petra Jilma-Stohlawetz, MD, Michael Fillitz, MD, Thomas Schenk, MD, Gary Patou, MD, Sandip Panicker, PhD, Graham C Parry, PhD, James C Gilbert, MD, Bernd Jilma, MD

Blood (2017) 130 (Supplement 1): 703.

https://doi.org/10.1182/blood.V130.Suppl_1.703.703

Published: 2017

Journal Articles

Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

Emir Hadzijusufovic, DVM, Gregor Hoermann, MD, Susanne Herndlhofer, Wolfgang R. Sperr, MD, Bernd Jilma, MD, Gerit H. Schernthaner, MD, Peter Valent, MD

Blood (2017) 130 (Supplement 1): 1619.

https://doi.org/10.1182/blood.V130.Suppl_1.1619.1619

Published: 2017

Journal Articles

Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)

Bernd Jilma, MD, James C Gilbert, MD, Sandip Panicker, PhD, Graham C Parry, PhD, Michael Fillitz, MD, Schenk Thomas, Christian Sillaber, MD, Johann Bartko, MD, Ulrich Jaeger, MD

Blood (2016) 128 (22): 2435.

https://doi.org/10.1182/blood.V128.22.2435.2435

Published: 2016

Journal Articles

Natural IgM Against Oxidation-Specific Epitopes Inhibit Microvesicle-Driven Coagulation

Georg Obermayer, MD, Taras Afonyushkin, PhD, Florian Puhm, MSc, Michael Schwameis, MD, Bernd Jilma, MD, Christoph J Binder, MD PhD

Blood (2016) 128 (22): 2562.

https://doi.org/10.1182/blood.V128.22.2562.2562

Published: 2016

NARROW

Rondaptivon Pegol (BT200) to Correct Thrombocytopenia in a Peri-Interventional Setting in Type 2B Von Willebrand Disease (VWD)

The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1

Recombinant Human Diamine Oxidase Against Histamine Induced Shock - Implications for Mast Cell Activation Syndrome

Using a Quality Improvement Activity to Enhance the Knowledge, Competence and Confidence of Clinicians Managing Patients with Cold Agglutinin Disease

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CASCADE)

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis

Association of ABO Blood Group with Bleeding Severity in Patients with Bleeding of Unknown Cause

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy

Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)

Natural IgM Against Oxidation-Specific Epitopes Inhibit Microvesicle-Driven Coagulation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only